https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33412 Wed 31 Oct 2018 14:52:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35871 Wed 29 Apr 2020 14:11:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45020 +/HER _2- , HR⁺/HER₂₊ , HR^-/HER ₂₊, HR^-/HER_2-). On average, women were 56 years of age at diagnosis and were followed for a median of 3.7 years. The majority were white (80%), had private health insurance (50%), and presented with poorly differentiated tumors (57%). Approximately 46% of the cancers were >5 cm. Most patients underwent mastectomy (94%) and received radiotherapy (71%). Differences by biologic subtypes were observed for grade, lymph node invasion, race, and tumor size (p < 0.0001). Patients experiencing pathologic complete response (pCR, 12%) vs. non-pCR had superior 5-year overall survival (OS) (77% vs. 54%) (p < 0.0001). Survival was poor for triple-negative (TN) tumors (37%) vs. other biologic subtypes (60%) (p < 0.0001). On multivariable analysis, TN-IBC, positive margins, and not receiving either chemotherapy, hormonal therapy or radiotherapy were independently associated with poor 5-year survival (p < 0.0001). In this analysis of IBC, categorized by biologic subtypes, we observed significant differential tumor, patient and treatment characteristics, and OS.]]> Wed 26 Oct 2022 10:17:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31264 Q75 (4.5) and lymphocyte nadir values Wed 23 Feb 2022 16:02:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33411 Wed 19 Jan 2022 15:18:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33437 Wed 19 Jan 2022 15:16:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30275 Wed 11 Apr 2018 15:08:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38162 75 years (RR = 2.3, p = 0.0026), female (RR = 1.6, p = 0.019), 5-meter walk test (5MWT) >7s (RR = 2.0, p = 0.0002) and not using home oxygen (RR = 2.9, p = 0.0084) were identified as independent predictive factors for discharge to a SNF. We report a parsimonious risk-stratification model that estimates the probability of being discharged to a SNF following TAVR. Our findings will facilitate making informed treatment decisions regarding this older patient population.]]> Wed 04 Aug 2021 18:58:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30618 Wed 02 Mar 2022 14:25:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36417 Tue 28 Apr 2020 16:16:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35636 Tue 24 Sep 2019 14:13:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33438 Tue 03 Sep 2019 18:19:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33410 65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.]]> Tue 03 Sep 2019 18:19:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35748 Thu 28 Nov 2019 12:43:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30386 Thu 21 Oct 2021 12:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33745 +_NE) were positively associated with POAF, whereas DA (p = 0.0034) levels in the 4th quartile (Q4⁺_NE) were inversely associated with POAF. Adjusting for age, heart failure (HF), and history of atrial fibrillation, the composite pre-operative (adrenergic) plasma marker (Q4⁺_NE V Q4^-_DA) was associated with a 4-fold increased occurrence of POAF (adjusted p = 0.0001). No association between plasma MAO-B and POAF was observed. Conclusions: Our results suggest that pre-operative adrenergic tone is an important factor underlying POAF. This information provides evidence that assessment of plasma catecholamines may be a low-cost method that is easy to implement for predicting which patients are likely to develop POAF. More investigation in a multicentric setting is needed to validate our results.]]> Thu 17 Feb 2022 09:31:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33646 1500 American College of Surgeons Commission on Cancer-accredited facilities, patients receiving PECT were shown to survive longer than those receiving POCRT.]]> Thu 17 Feb 2022 09:28:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30177 P _Trend < .001). Conclusions: COPD and PLOS are 2 of many factors that affect long-term mortality in postoperative CABG patients. Aggressive treatment strategies aimed at early weaning off of mechanical ventilation and prevention of reintubation among COPD patients must be considered carefully as a means to reduce length of stay after CABG. Our results also have important implications for the long-term management of these patients and strategies for containing costs over the life course of the patient.]]> Sat 24 Mar 2018 07:26:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30184 interaction = 0.0009).]]> Mon 23 Sep 2019 14:02:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32029 Mon 23 Sep 2019 13:08:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50236 Mon 10 Jul 2023 14:50:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45478 65 years of age) presented with stage I-III pancreatic cancer. The majority of patients had tumors >2 cm size (82%), grade I/II (65%), lymphatic invasion (LI) (66%), and negative margins (76%). A survival advantage for adjuvant therapy was observed among all patients, independent of their risk-profile. For example, a patient =65 years of age, with early stage cancer (size =2 cm, grade I/II, -ve LI, -ve margins) who received adjuvant therapy had a 62% probability of being alive beyond three years (95%CI = 59%-66%). In contrast, the survival probability decreased to 53% (95%CI = 59%-66%) without adjuvant therapy. Conclusions: These results provide surgeons and patients with more accurate information regarding long-term survival, as well as the benefit of opting for adjuvant therapy after successful pancreatic surgery.]]> Fri 28 Oct 2022 14:36:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32036 Fri 01 Apr 2022 09:24:05 AEDT ]]>